Topics

Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

16:01 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the closing of its previously announced r...

Other Sources for this Article

Investor Contacts
Timothy McCarthy
LifeSci Advisors, LLC
Tel: 212-915-2564
tim@lifesciadvisors.com

NEXT ARTICLE

More From BioPortfolio on "Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market"

Quick Search

Relevant Topic

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...